Bookmark

Add to MyYahoo RSS

Geron News

News on Geron (Ticker: GERN) continually updated from thousands of sources around the net.

Wednesday Apr 16 | BayStreet.ca

Prana Biotechnology Stock Hits New Low

Prana Biotechnology share value has been tumbling over the last month, closing at $1.74 Apr. 15, down 15 cents from the previous day's close of $1.89.

Comment?

Related Topix: Biotech, Science / Technology, Alzheimer's, Health, Startups

Mon Apr 14, 2014

Seeking Alpha

Are These Three Biotech Companies Still Worth A Gamble?

For all the positive results from NeuVax clinical studies, the ethical shortcomings of Galena's management mean that the future of the company is uncertain.

Comment?

Related Topix: Startups, Healthcare Law, Law, Food and Drug Administration

Tue Apr 08, 2014

Nature Biotechnology

First Rounders: Michael West

West was the first CEO for Geron, which he founded in 1990. He was also CEO of Advanced Cell Technology and is now CEO of BioTime.

Comment?

Related Topix: Startups, Advanced Cell Technology

Mon Apr 07, 2014

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Questcor Pharmaceuticals Inc. over the Proposed Sale of the Company to Mallinckrodt plc )--The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current s... )--Morgan Stanley Income ... (more)

Comment?

Related Topix: Manufacturing, Industrial Machines, Sealed Air Corporation, Startups

BioSpace

Geron Corporation Analyst Report: High Potential High Risk...

Geron Corporation Analyst Report: High Potential High Risk Biopharmaceutical Firm Seeking To Advance Novel Innovative Cancer Treatment For Myeloid Malignancies By BrokerBank Securities, Inc. /PRNewswire/ -- Geron Corporation , an emerging competitor, is developing a telomerase inhibitor called Imetelstat in hematologic myeloid malignancies.

Comment?

Related Topix: Startups, Cancer, Medicine, Health, Corporate / Securities Law, Law

Fri Apr 04, 2014

AmericanBankingNews.com

Geron Given Neutral Rating at Zacks

's stock had its "neutral" rating reaffirmed by Zacks in a research note issued on Friday, AnalystRatings.Net reports.

Comment?

Related Topix: Startups

Wed Apr 02, 2014

AmericanBankingNews.com

Insider Selling: Olivia Kyusuk Bloom Sells 7,435 Shares of Geron Stock

Geron CFO Olivia Kyusuk Bloom sold 7,435 shares of the stock on the open market in a transaction dated Tuesday, April 1st.

Comment?

Related Topix: Startups

AmericanBankingNews.com

Insider Selling: Geron EVP Sells 12,310 Shares of Stock

Geron EVP Melissa Kelly Behrs sold 12,310 shares of the stock in a transaction that occurred on Tuesday, April 1st.

Comment?

Related Topix: Startups

Hispanic Business

Attention Geron Corporation Investors: Geron Misled Investors...

Geron is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignanciesis .

Comment?

Related Topix: Startups

Thu Mar 27, 2014

Seeking Alpha

Continued Treatment Of Myelofibrosis Responders With Imetelstat Bodes Well For Geron Investors

Worst case scenario is Imetelstat will only be allowed to be used on late stage Myelofibrosis patients who have failed other treatments.

Comment?

Related Topix: Startups, Healthcare Law, Law, Financial Markets

Tue Mar 25, 2014

Hispanic Business

Tuesday's ETF Movers: GDXJ, XBI

In trading on Tuesday, the Junior Gold Miners ETF is outperforming other ETFs, up about 1.5% on the day.

Comment?

Related Topix: Startups

Pharmaceutical Online

SFGate Highlights Bureaucratic Slog And Drug Safety Issues

SF Gate highlighted the issue of lengthy regulatory approval processes , labeled by some as bureaucratic slog, and drug safety issues in its recent article "Long, Winding Road to Approval for New Drugs."

Comment?

Related Topix: Healthcare Law, Food and Drug Administration, Law, Startups

Mon Mar 24, 2014

Sys-Con Media

Attention Geron Corporation Investors: Geron Misled Investors...

The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between , following an announcement by the company that it received notice from the U.S. Food and Drug Administration that its Investigational New Drug application for Imetelstat had been placed on full clinical hold.

Comment?

Related Topix: Startups, Healthcare Law, Law, Food and Drug Administration

Sys-Con Media

Geron Corporation Stockholders Encouraged to Contact Securities Law Firm about Investigation

Concerned GERN investors who purchased between announcement that the FDA put Geron's Investigational New Drug application for imetelstat on full clinical hold, stock plummeted more than 60%," said securities lawyer Hamilton Lindley.

Comment?

Related Topix: Healthcare Law, Startups, Law

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••
•••